Cargando…
Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430
Filoviruses are emerging pathogens and causative agents of viral haemorrhagic fever. Case fatality rates of filovirus disease outbreaks are among the highest reported for any human pathogen, exceeding 90% (ref. 1). Licensed therapeutic or vaccine products are not available to treat filovirus disease...
Autores principales: | Warren, Travis K., Wells, Jay, Panchal, Rekha G., Stuthman, Kelly S., Garza, Nicole L., Van Tongeren, Sean A., Dong, Lian, Retterer, Cary J., Eaton, Brett P., Pegoraro, Gianluca, Honnold, Shelley, Bantia, Shanta, Kotian, Pravin, Chen, Xilin, Taubenheim, Brian R., Welch, Lisa S., Minning, Dena M., Babu, Yarlagadda S., Sheridan, William P., Bavari, Sina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095208/ https://www.ncbi.nlm.nih.gov/pubmed/24590073 http://dx.doi.org/10.1038/nature13027 |
Ejemplares similares
-
BCX4430 – A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease
por: Taylor, Raymond, et al.
Publicado: (2016) -
An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral
por: Julander, Justin G., et al.
Publicado: (2021) -
Shedding Light on Filovirus Infection with High-Content Imaging
por: Pegoraro, Gianluca, et al.
Publicado: (2012) -
A Limited Structural Modification Results in a Significantly More Efficacious Diazachrysene-Based Filovirus Inhibitor
por: Selaković, Života, et al.
Publicado: (2012) -
Correlates of Immunity to Filovirus Infection
por: Bradfute, Steven B., et al.
Publicado: (2011)